{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T05:14:58Z","timestamp":1788066898405,"version":"build-2784847793"},"reference-count":42,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Biologics\u2019 efficacy in relieving cough and dyspnea in severe eosinophilic asthma (SEA) is under-characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This exploratory analysis evaluated the efficacy of benralizumab separately in reducing cough and\/or dyspnea in patients with SEA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Post-hoc analysis of a phase III, randomized, double-blind, placebo-controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>MIRACLE (NCT03186209) data were used, involving patients aged 12\u201375\u2009years with uncontrolled SEA. Patients reporting baseline frequent cough and\/or dyspnea based on St George\u2019s Respiratory Questionnaire (SGRQ) items were analyzed. Changes in cough frequency, cough-specific HRQoL, and dyspnea frequency measured through relevant SGRQ items were evaluated over 48\u2009weeks. Subgroup analyses based on baseline blood eosinophil counts (bEOS \u2a7e300 cells\/\u03bcL) were conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 383 patients (benralizumab: 189; placebo: 194) with baseline frequent cough and 304 with baseline frequent dyspnea (benralizumab: 151; placebo: 153) were included. The proportions of patients transitioning to non-frequent cough with benralizumab versus placebo were 54.0% versus 39.7% at Week 8 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0051), and 59.3% versus 56.7% at Week 48. Improvements in cough-related SGRQ items, including reductions in cough-related pain\/fatigue, less sleep disturbance, and decreased embarrassment in public, occurred earlier with benralizumab compared to placebo and were sustained through Week 48. Among patients with higher inflammatory burden (baseline bEOS \u2a7e300 cells\/\u03bcL), the prevalence of frequent cough at baseline was higher. In this subgroup, a higher proportion transitioned to non-frequent cough with benralizumab versus placebo at both Week 8 (55.3% vs 37.1%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0027) and Week 48 (59.8% vs 52.1%). Differential improvements in cough-related SGRQ items favoring benralizumab were consistently observed. Reductions in dyspnea frequency followed a similar pattern, with benralizumab showing greater improvements versus placebo at both Week 8 (64.2% vs 47.1%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0026) and Week 48 (75.5% vs 63.4%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0221).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Benralizumab showed potential to rapidly reduce cough and\/or dyspnea frequency, and to improve cough-specific HRQoL more quickly than placebo in patients with SEA, with sustained advantage in cough-related SGRQ items through Week 48. Improvements were pronounced in patients with higher baseline bEOS, potentially reflecting a higher disease burden. However, as this was an exploratory analysis, further validation using cough-specific clinical endpoints is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov, NCT03186209,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03186209\">https:\/\/clinicaltrials.gov\/study\/NCT03186209<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17534666261471304","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:04:40Z","timestamp":1787889880000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of benralizumab in reducing cough and\/or dyspnea frequency, and improving cough-specific health-related quality of life in patients with severe eosinophilic asthma in Asia"],"prefix":"10.1177","volume":"20","author":[{"given":"Kefang","family":"Lai","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejun","family":"Sun","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranran","family":"Dai","sequence":"additional","affiliation":[{"name":"Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxiang","family":"Xu","sequence":"additional","affiliation":[{"name":"Northern Jiangsu People\u2019s Hospital, Yangzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhao","sequence":"additional","affiliation":[{"name":"Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[{"name":"China Medical Affairs Department, AstraZeneca, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-9651","authenticated-orcid":false,"given":"Calvin N.","family":"Ho","sequence":"additional","affiliation":[{"name":"Late-Stage Respiratory &amp; Immunology, AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5937-8039","authenticated-orcid":false,"given":"Viktoria","family":"Werkstr\u00f6m","sequence":"additional","affiliation":[{"name":"Late-Stage Respiratory &amp; Immunology, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cohen","sequence":"additional","affiliation":[{"name":"Late-Stage Respiratory &amp; Immunology, AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0730-7850","authenticated-orcid":false,"given":"Sofia","family":"Necander","sequence":"additional","affiliation":[{"name":"Late-Stage Respiratory &amp; Immunology, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanshan","family":"Zhong","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.04.013"},{"key":"e_1_3_4_3_2","unstructured":"Global Initiative for Asthma. Difficult-to-treat & severe asthma in adolescent and adult patients https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/11\/GINA-Severe-Asthma-Guide-2024-WEB-WMS.pdf (2024 accessed 10 October 2025)."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S418145"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00588-2019"},{"key":"e_1_3_4_6_2","article-title":"Severe eosinophilic asthma in Chinese C-BIOPRED asthma cohort","volume":"12","author":"Zhang Q","year":"2022","unstructured":"Zhang Q, Fu X, Wang C, et al. Severe eosinophilic asthma in Chinese C-BIOPRED asthma cohort. Clin Transl Med 2022; 12: e710.","journal-title":"Clin Transl Med"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-017-0520-2"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-024-00710-5"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00442-2022"},{"key":"e_1_3_4_10_2","article-title":"How respiratory symptoms impact asthma-related quality of life in severe asthmatics","volume":"62","author":"Louis G","year":"2023","unstructured":"Louis G, Schleich F, Guillaume M, et al. How respiratory symptoms impact asthma-related quality of life in severe asthmatics. Eur Respir J 2023; 62: OA1526.","journal-title":"Eur Respir J"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.107098"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106921"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.06714"},{"key":"e_1_3_4_14_2","first-page":"32","article-title":"Phenotype overlap in the natural history of asthma","author":"Ricciardolo FLM","year":"2023","unstructured":"Ricciardolo FLM, Guida G, Bertolini F, et al. Phenotype overlap in the natural history of asthma. Eur Respir Rev 2023; 32:","journal-title":"Eur Respir Rev"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.720538"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-81745-9"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13601-015-0069-4"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03205-2021"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00100-2015"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.12789"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107578"},{"key":"e_1_3_4_22_2","first-page":"863","article-title":"Real-world multicenter experience with mepolizumab and benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months","volume":"2021","author":"Kayser MZ","unstructured":"Kayser MZ, Drick N, Milger K, et al. Real-world multicenter experience with mepolizumab and benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months. J Asthma Allergy 2021: 863\u2013871.","journal-title":"J Asthma Allergy"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107611"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-023-02539-7"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00672-5"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1108663"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.04.048"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-020-00391-w"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.04.022"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00187-X"},{"key":"e_1_3_4_33_2","first-page":"208","article-title":"Guidelines for the prevention and management of bronchial asthma (2024 edition)","volume":"48","author":"Chinese Thoracic Society CMA","year":"2025","unstructured":"Chinese Thoracic Society CMA. Guidelines for the prevention and management of bronchial asthma (2024 edition). Zhonghua Jie He He Hu Xi Za Zhi 2025; 48: 208\u2013248.","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13251"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01196-2014"},{"key":"e_1_3_4_36_2","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/05\/GINA-2024-Strategy-Report-24_05_22_WMS.pdf (2024 accessed 10 October 2025)."},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1159\/000530392"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1159\/000525846"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.04.015"},{"key":"e_1_3_4_40_2","article-title":"Psychometric properties of the St George\u2019s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials","volume":"5","author":"Swigris JJ","year":"2018","unstructured":"Swigris JJ, Wilson H, Esser D, et al. Psychometric properties of the St George\u2019s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials. BMJ Open Respir Res 2018; 5: e000278.","journal-title":"BMJ Open Respir Res"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-022-00527-0"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.10.008"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.09.008"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666261471304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17534666261471304","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666261471304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T04:16:36Z","timestamp":1788063396000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17534666261471304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":42,"alternative-id":["10.1177\/17534666261471304"],"URL":"https:\/\/doi.org\/10.1177\/17534666261471304","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/17534666261471304\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261471304\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261471304\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261471304\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261471304\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261471304\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261471304\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261471304\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"17534666261471304"}}